Autopsy report · NCT05466240

Study of AT-752 in Patients With Dengue Infection

“Sponsor decision to deprioritize the dengue program”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 9 months before it stopped.
• 21 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Atea Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Dengue Fever

Interventions

AT-752; Placebo

Participants

21

Sites

32

Countries

Brazil, Colombia, Ecuador, India, Malaysia, Peru, Philippines, Taiwan, Thailand, Vietnam

Trials that died the same way

• Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
  “Strategic sponsor decision” (59% match in meaning)
• Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
  “Sponsor decision” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.